Rejigging The Benefit-Risk Balance For Advanced Therapies In The EU

 
• By Neena Brizmohun

The European Medicines Agency’s Committee for Advanced Therapies has revealed its priorities for addressing the challenges manufacturers face in the fast-growing field of advanced therapies.

T-cells attacking cancer_1200x675
The European Medicines Agency's advanced therapy committee has released its 2017 work plan

More from R&D

More from Pink Sheet